WAT (US)


March 5, 2025

Life Science Tools: Court Intervention & NIH’s New Management

By John Leppard

Events today support our view that NIH grant funding benefitting life science tools (LST) manufacturers will likely stabilize, and that the Trump administration’s Feb. 7 announcement of a 15% cap on indirect costs for all…

Read More >>

February 8, 2025

Life Science Tools: NIH Indirect Cost Cut Risks

By John Leppard

NIH’s surprise announcement Friday of a 15% cap on indirect costs for both new and existing grants will likely trigger fresh uncertainty for life science tools (LST) manufacturers. While indirect costs are technically distinct from…

Read More >>

November 15, 2024

RFK to HHS: Biopharma / Lifesciences Smoke or Fire?

By John Leppard

Key Takeaways: We are initially skeptical that Trump’s selection of Robert F. Kennedy Jr. (RFK) to lead HHS can survive Senate confirmation but, if we are wrong, would note that any HHS secretary is constrained…

Read More >>